pamidronate has been researched along with Compression Fractures in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pamidronate treatment in children with all types of OI increased LS BMD, decreased fracture rate, and improved vertebral compression fractures." | 7.83 | Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. ( Åström, E; Grigelioniene, G; Kindmark, A; Lindahl, K; Ljunggren, Ö; Malmgren, B; Rubin, CJ; Söderhäll, S, 2016) |
| " To assess the role of biochemical bone markers in classification of children with osteogenesis imperfecta (OI), their possible association with vertebral compression fractures in milder forms of OI and their role in monitoring of intravenous pamidronate (APD) treatment." | 7.76 | Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta. ( Aström, E; Eksborg, S; Magnusson, P; Söderhäll, S, 2010) |
| "Our aim was to compare the analgesic efficacy of pamidronate (PAM) and synthetic human calcitonin (CT) in intravenous infusion for recent painful benign vertebral compression in a randomised prospective double-blind study." | 5.12 | Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study. ( Cantagrel, A; Cantogrel, S; Constantin, A; Jamard, B; Laroche, M; Mazières, B; Zabraniecki, L, 2006) |
| "We performed a randomized, double-blind, controlled clinical trial comparing intravenous pamidronate and placebo for pain relief in recent osteoporotic vertebral compression fractures (VCF)." | 5.12 | Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. ( Armingeat, T; Brondino, R; Lafforgue, P; Legré, V; Pham, T, 2006) |
| "Pamidronate treatment in children with all types of OI increased LS BMD, decreased fracture rate, and improved vertebral compression fractures." | 3.83 | Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. ( Åström, E; Grigelioniene, G; Kindmark, A; Lindahl, K; Ljunggren, Ö; Malmgren, B; Rubin, CJ; Söderhäll, S, 2016) |
| " To assess the role of biochemical bone markers in classification of children with osteogenesis imperfecta (OI), their possible association with vertebral compression fractures in milder forms of OI and their role in monitoring of intravenous pamidronate (APD) treatment." | 3.76 | Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta. ( Aström, E; Eksborg, S; Magnusson, P; Söderhäll, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palomo, T | 1 |
| Fassier, F | 1 |
| Ouellet, J | 1 |
| Sato, A | 1 |
| Montpetit, K | 1 |
| Glorieux, FH | 1 |
| Rauch, F | 1 |
| Lindahl, K | 1 |
| Kindmark, A | 1 |
| Rubin, CJ | 1 |
| Malmgren, B | 1 |
| Grigelioniene, G | 1 |
| Söderhäll, S | 2 |
| Ljunggren, Ö | 1 |
| Åström, E | 2 |
| Magnusson, P | 1 |
| Eksborg, S | 1 |
| Jenkinson, E | 1 |
| Laroche, M | 1 |
| Cantogrel, S | 1 |
| Jamard, B | 1 |
| Constantin, A | 1 |
| Zabraniecki, L | 1 |
| Cantagrel, A | 1 |
| Mazières, B | 1 |
| Armingeat, T | 1 |
| Brondino, R | 1 |
| Pham, T | 1 |
| Legré, V | 1 |
| Lafforgue, P | 1 |
| Lucarelli, S | 1 |
| Borrelli, O | 1 |
| Paganelli, M | 1 |
| Capocaccia, P | 1 |
| Frediani, T | 1 |
| Ferri, F | 1 |
| Cucchiara, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Intraoperative Use of Tranexamic Acid in Reducing Blood Loss During Telescoping Nail Application in Osteogenesis Imperfecta - Randomized Control Trials[NCT05321199] | 20 participants (Actual) | Interventional | 2022-05-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pamidronate and Compression Fractures
| Article | Year |
|---|---|
Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: do bisphosphonates relieve pain caused by acute osteoporotic vertebral compression fractures?
Topics: Administration, Oral; Aged; Back Pain; Bone Density Conservation Agents; Diphosphonates; Female; Fra | 2011 |
2 trials available for pamidronate and Compression Fractures
| Article | Year |
|---|---|
Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study.
Topics: Aged; Aged, 80 and over; Analgesics; Bone Density Conservation Agents; Calcitonin; Diphosphonates; F | 2006 |
Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study.
Topics: Acute Disease; Aged; Aged, 80 and over; Analgesics; Back Pain; Bone Density Conservation Agents; Dip | 2006 |
4 other studies available for pamidronate and Compression Fractures
| Article | Year |
|---|---|
Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Topics: Absorptiometry, Photon; Adolescent; Anthropometry; Bone and Bones; Bone Density; Bone Density Conser | 2015 |
Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Topics: Body Height; Bone Density; Child; Child, Preschool; Collagen Type I; Diphosphonates; DNA Mutational | 2016 |
Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation A | 2010 |
Vertebral fractures and increased sensitivity to corticosteroids in a child with ulcerative colitis: successful use of pamidronate.
Topics: Back Pain; Bone Density; Bone Density Conservation Agents; Child; Colitis, Ulcerative; Diphosphonate | 2006 |